Funded Projects › FP7
MODHEP · Systems biology of liver cancer: an integrative genomic-epigenomic approach
Cancer is a complex disease involving multiple genetic and epigenetic events occurring, and influencing each other, over a long period of time. Understanding cancer, and ultimately developing effective targeted therapies, will therefore require that mutations and epigenetic alterations be systematically investigated during the multiple stages of disease development, from identifiable pre-neoplastic phases to overt cancer. Until now, no systematic effort has been undertaken to investigate these multiple layers of genome organization and function during cancer development. MODHEP aims at providing a 360° understanding of liver cancer, one of the most common types of tumors and, because of the homogeneity of the hepatic tissue, the most experimentally tractable one. The consortium brings together elite European scientists in the fields of genetics, chromatin regulation, genomics, liver cancer, computational and systems biology. This combination of skills will allow us to investigate and model at unprecedented resolution the chain of events leading from environmental perturbations and the occurrence of driver mutations to preneoplastic disease and cancer. Our experimental plan reflects some grounded assumptions: 1. cancer cannot be modeled without detailed information on the preneoplastic stages of disease; 2. genetic heterogeneity in humans would make systems-level modeling non realistic from a practical point of view. Both of these limitations are bypassed by the use of well-defined mouse models, followed by evaluation of the main conclusions in clinical samples; 3. many early stage driving events in cancer represent epigenetic alterations, which are invisible to classical genetic analysis, and are confounded by secondary and tertiary events in established tumors. Our approach will enable the identification of therapeutically relevant early-stage genetic and epigenetic alterations and the definition of their interplay in tumor development and maintenance.
Consortium · 18 organisations
FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA
IT · €687,842
MATER MEDICAL RESEARCH INSTITUTE LIMITED
AU · €577,570
INSTITUT PASTEUR
FR · €800,000
FONDAZIONE TELETHON ETS
IT · €825,231
ISTITUTO EUROPEO DI ONCOLOGIA SRL
IT · €1,762,573
ABGI FRANCE
FR · €295,570
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
FR · €760,004
RIKEN THE INSTITUTE OF PHYSICAL ANDCHEMICAL RESEARCH
JP · €951,000
KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN - KNAW
NL · €805,000
WEIZMANN INSTITUTE OF SCIENCE
IL · €647,999
BIOBYTE SOLUTIONS GMBH
DE · €318,600
THE BABRAHAM INSTITUTE
UK · €797,486
INSTITUT CURIE
FR · €1,362,500
MEDICAL RESEARCH COUNCIL
UK · €11,904
THE UNIVERSITY OF EDINBURGH
UK · €493,177
NOVAMEN SAS
FR · €167,210
FONDAZIONE SANTA LUCIA
IT · €574,148
KING'S COLLEGE LONDON
UK · €99,085
Research fields
← Find collaborators and more funded projects
Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.